Restarting Thalidomide-Dexamethasone Regimen in a Post-Abortive Female with Multiple Myeloma: Effective Clinical Response Possible

• Main Authors: Suhailur Rehman, S. H. Arif, Amit Kumar, A. Q. Khan
• Format: Article
• Language: English
• Published: Tehran University of Medical Sciences 2017-07-01
• Series: International Journal of Hematology-Oncology and Stem Cell Research
• Subjects: Multiple myeloma; Post-aborted woman; Thalidomide-dexamethasone therapy; High β-hCG levels
• Online Access: https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/840

Nowadays, the prevalence of Multiple Myeloma (MM) seems to have been increasing among young females. Here, we report that thalidomide is contraindicated in pregnant women diagnosed with MM and those desirous of subsequent pregnancy. In this case report, we compared the clinical response of Thalidomide-Dexamethasone therapy in a post-abortive woman with persistently elevated β-hCG levels due to retained products of conception, undergoing hysterectomy later. This case report underlines the clinical significance of age, the effect of Thalidomide-Dexamethasone therapy even after initial discontinuation and the response to high β-hCG levels.